PCSK9 in metabolism and diseases

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Science

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease crucial for regulating plasma low-density lipoprotein (LDL) and cholesterol levels.
• PCSK9 mediates the liver's endolysosomal degradation of the LDL receptor (LDLR), impacting cholesterol homeostasis.
• Dysregulated PCSK9 activity leads to elevated LDL cholesterol, contributing to conditions like hypercholesterolemia, hyperlipidemia, and cardiovascular disease (CVD).

Purpose of the Study:

• To comprehensively review the regulatory role of PCSK9 in lipid and cholesterol metabolism.
• To elucidate PCSK9's involvement in the pathophysiology of diseases including CVD, infections, cancer, and sepsis.
• To discuss pharmaceutical and non-pharmaceutical strategies for targeting PCSK9 in therapeutic management.

Main Methods:

• Literature review of existing clinical and experimental evidence.
• Analysis of PCSK9's function in lipid metabolism and disease pathogenesis.
• Exploration of metabolic hormone regulation of PCSK9 and its therapeutic implications.

Main Results:

• PCSK9 plays a critical role in cholesterol regulation through LDLR degradation.
• PCSK9 is implicated in metabolic anomalies, inflammation, and mitochondrial homeostasis.
• Metabolic hormones significantly influence PCSK9 expression and levels, affecting cardiovascular and metabolic functions.

Conclusions:

• PCSK9 is a key regulator of cholesterol metabolism with implications in various diseases.
• Understanding PCSK9's regulatory network offers therapeutic opportunities for metabolic and cardiovascular conditions.
• Targeting PCSK9 presents a promising strategy for managing hypercholesterolemia and related diseases.